Company Overview of Oxford Gene Technology IP Limited
Oxford Gene Technology IP Limited provides genetics research and biomarker solutions to advance molecular medicine worldwide. Its products include CytoSure international standards for cytogenomic arrays; CytoSure ISCA UPD arrays that allow the detection of DNA copy number variation with whole chromosome uniparental disomy; CytoSure ISCA UPD arrays that combines long oligo aCGH probes for copy number variation detection; and CytoSure Syndrome Plus v2 arrays for the detection of DNA aberrations across the genome. The company's products also comprise Aneuploidy arrays for the simplified detection of chromosome imbalances; CytoSure single cell aneuploidy arrays to detect aneuploidies when workin...
Begbroke Science Park
Begbroke, OX5 1PF
Founded in 1995
Key Executives for Oxford Gene Technology IP Limited
Executive Vice President of R&D
Compensation as of Fiscal Year 2013.
Oxford Gene Technology IP Limited Key Developments
Oxford Gene Technology IP Ltd. Launches PGS Array to Improve the Chances of Successful IVF
Jun 3 13
Oxford Gene Technology IP Ltd. announced the launch of a new pre-implantation genetic screening (PGS) array aimed at improving the chances of successful in-vitro fertilisation (IVF). The array detects chromosome number abnormalities (aneuploidy) across all 24 human chromosomes using DNA amplified from a single cell from an early-stage embryo. This allows selection of an embryo with a normal chromosomal content. The number of women receiving IVF has increased steadily, however the percentage of IVF treatments resulting in viable pregnancies is still comparatively low with chromosomal aneuploidy a leading genetic cause of unsuccessful IVF. It has been reported that 75% of eggs in women over 37 and 23% of eggs in younger women are chromosomally abnormal1. OGT’s CytoSure™ Single Cell Aneuploidy array is the first commercially available oligonucleotide aCGH product designed specifically for PGS. The array is sensitive enough to work with small amounts of amplified DNA from a single cell from an early-stage embryo. Unlike technologies such as fluorescence in situ hybridisation (FISH), the array can detect aneuploidies across the whole genome. The array allows eight samples to be run simultaneously, which is more than existing bacterial artificial chromosome (BAC) aneuploidy arrays, minimising sample-to-sample variation by reducing technical noise. The array is complemented by OGT’s CytoSure Interpret Software which analyses the data generated to produce simple, easy-to-use results. The ability to clearly identify aneuploidy is vital to make a confident and informed decision as to the chromosomal content of an embryo. The array has also been research-validated to investigate aneuploidies in first polar bodies, single blastomeres and trophectoderm biopsies.
Oxford Gene Technology Launches Ground-Breaking 58-Gene Tumour Profiling Service
May 28 13
Oxford Gene Technology (OGT) has furthered its commitment to fighting cancer with the launch of a new solid tumour profiling next-generation sequencing service to advance vital research into personalized cancer care. OGT’s SureSeq Solid Tumour Panel Sequencing Service profiles the mutations of patient tumours for 58 cancer-associated genes prioritized by Cancer Research UK and leading cancer researchers. The genes include those important in breast, prostate, ovarian, lung and colorectal cancers, many with currently actionable mutations. OGT also offers researchers the flexibility to further customize the panel by adding additional genes of interest. OGT has applied its extensive expertise in probe design to Agilent’s industry-leading SureSelect hybridisation methodology, to deliver an assay with unparalleled uniformity of targeted sequence enrichment, excellent accuracy and sensitivity of variant detection across full genes, and robust performance with FFPE samples. All results are delivered in a comprehensive interactive web-based report to enable informed interpretation of results. The SureSeq Solid Tumour Panel Sequencing Service utilises an enrichment panel comprising the full coding regions of 58 prioritized cancer genes. The aim of the panel is to improve cancer care by providing individualized patient profiles facilitating the implementation of personalized treatment strategies. The panel was research-validated for use with fresh, frozen and formalin-fixed, paraffin-embedded (FFPE) samples and focuses on breast, prostate, ovarian, lung and colorectal cancers. OGT also offers the user flexibility to add genes of interest to the panel as part of the service.
Similar Private Companies By Industry
Recent Private Companies Transactions
Most Searched Private Companies
Sponsored Financial Commentaries